|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1996-3-1
|
|
pubmed:abstractText |
The purpose of these studies was to determine whether systemic administration of recombinant interleukin 12 (rIL-12) is able to potentiate an initial, but insufficient T-cell antitumor response. Mice challenged with carcinoma cells engineered to release interleukin 2 (IL-2) and displaying such a response received single or multiple i.p. injections of rIL-12. This combination of systemic rIL-12 and local IL-2 increased the percentage of mice that rejected two different IL-2 gene-transduced tumors. In another set of experiments more closely resembling a clinical situation, IL-2 gene-transduced tumors were used as vaccines in an attempt to cure mice bearing wild-type parental tumors. The combination of these vaccines with systemic rIL-12 cured mice more effectively than rIL-12 and IL-2 gene-transduced tumor vaccines alone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0008-5472
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
467-70
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8564954-Adenocarcinoma,
pubmed-meshheading:8564954-Animals,
pubmed-meshheading:8564954-Cell Division,
pubmed-meshheading:8564954-Chemotherapy, Adjuvant,
pubmed-meshheading:8564954-Colonic Neoplasms,
pubmed-meshheading:8564954-Combined Modality Therapy,
pubmed-meshheading:8564954-DNA, Complementary,
pubmed-meshheading:8564954-Drug Synergism,
pubmed-meshheading:8564954-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:8564954-Humans,
pubmed-meshheading:8564954-Immunotherapy, Adoptive,
pubmed-meshheading:8564954-Interleukin-12,
pubmed-meshheading:8564954-Interleukin-2,
pubmed-meshheading:8564954-Killer Cells, Natural,
pubmed-meshheading:8564954-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:8564954-Mice,
pubmed-meshheading:8564954-Mice, Inbred BALB C,
pubmed-meshheading:8564954-T-Lymphocytes,
pubmed-meshheading:8564954-Transduction, Genetic,
pubmed-meshheading:8564954-Vaccines
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells.
|
|
pubmed:affiliation |
Istituto Nazionale Tumori, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
